It’s a tough market right now for biotech IPOs, but one small company is taking the public leap Friday with a modest initial offering. Blue Water Vaccines raised $20 million in its IPO, pricing shares at $9 apiece late Thursday afternoon. The Cincinnati-based company will use the money primarily to advance a slate of preclinical […]
Due to the increasing incidence of diabetes, obesity and metabolic disease in the United States, it is estimated that one in four patients has some form of fatty liver disease. The impact of this on the healthcare system has been realized and is likely to increase over time. As primary care physicians continue to see […]
In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren’s disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.